High-risk Corneal Transplantation: Recent Developments and Future Possibilities
Open accessThe DOI matches its Crossref record.
Abstract
Human corneal transplantation (keratoplasty) is typically considered to have superior short- and long-term outcomes and lower requirement for immunosuppression compared to solid organ transplants because of the inherent immune privilege and tolerogenic mechanisms associated with the anterior segment of the eye. However, in a substantial proportion of corneal transplants, the rates of acute rejection and/or graft failure are comparable to or greater than those of the commonly transplanted solid organs. Critically, while registry data and observational studies have helped to identify factors that are associated with increased risk of corneal transplant failure, the extent to which these risk factors operate through enhancing immune-mediated rejection is less clear. In this overview, we summarize a range of important recent clinical and basic insights related to high-risk corneal transplantation, the factors associated with graft failure, and the immunological basis of corneal allograft rejection. We highlight critical research areas from which continued progress is likely to drive improvements in the long-term survival of high-risk corneal transplants. These include further development and clinical testing of predictive risk scores and assays; greater use of multicenter clinical trials to optimize immunosuppressive therapy in high-risk recipients and robust clinical translation of novel, mechanistically-targeted immunomodulatory and regenerative therapies that are emerging from basic science laboratories. We also emphasize the relative lack of knowledge regarding transplant outcomes for infection-related corneal diseases that are common in the developing world and the potential for greater cross-pollination and synergy between corneal and solid organ transplant research communities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions
Abraham, A. R., Maghsoudlou, P., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1184937 · Cited by 20
Xu, X., Wu, Y., Gu, R., Zhang, Z., Liu, X., Hu, Y., Li, X., Lin, D., & Bao, Z. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114351 · Cited by 14
Metadata
- Authors
- Armitage, W. J., Goodchild, C., Griffin, M. D., Gunn, D. J., Hjortdal, J., Lohan, P., Murphy, C. C., Pleyer, U., Ritter, T., Tole, D. M., & Vabres, B.
- Venue
- Transplantation
- Published
- 2019-12
- Volume
- 103
- Issue
- 12
- Pages
- 2468-2478
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2969969247
- Cited by
- 157
- References
- 0
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-risk Corneal Transplantation: Recent Developments and Future Possibilities. https://app.cochat.ai/papers/10.1097/tp.0000000000002938
- The paper
- Armitage, W. J., Goodchild, C., Griffin, M. D., Gunn, D. J., Hjortdal, J., Lohan, P., Murphy, C. C., Pleyer, U., Ritter, T., Tole, D. M., & Vabres, B. (2019). High-risk Corneal Transplantation: Recent Developments and Future Possibilities. Transplantation. https://doi.org/10.1097/tp.0000000000002938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.